lilly glp 1 drug Novo, weight-loss drugs should be first option obesity treatments, European doctors say Lilly orforglipron oral GLP-1 phase

Pistorius, E

The study was retrospective, relied on structured EHR data, and used coded definitions for recurrence rather than centrally adjudicated oncologic outcomes

The recovery benefit is measured against an exercise challenge

doi: 10.3389/fendo.2022.882998 Received 24 February 2022 Accepted 21 September 2022 Published 10 October 2022 Volume 13 - 2022 Edited by ke Sjholm, Gvle Hospital, Sweden Reviewed by Zhanna Belaya, Endocrinology Research Center, Russia

Although the evidence for the carcinogenicity of ethylene oxide in man is inadequate, epidemiological studies indicate that exposure to ethylene oxide (in mixtures with other chemicals) increases the risk of malignancies (section 8.6)

The primary endpoint was AUC 0 for plasma cagrilintide from baseline (day 1) to day 39 (end of study)